Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520287 | 0.84 | NPC1 (0.69) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL27750343 | 0.84 | NPC1 (0.68) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL27451737 | 0.84 | NPC1 (0.68) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL9492505 | 0.84 | HPGD (0.78) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL9492258 | 0.84 | HPGD (0.78) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL6356707 | 0.83 | NPC1 (1.00) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL10792384 | 0.82 | HPGD (0.81) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| SCHEMBL4706604 | 0.82 | NPC1 (0.66) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2990660 | 0.81 | NPC1 (0.64) | NPC1RAB9AHPGDPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4707532 | 0.81 | NPC1 (0.64) | NPC1RAB9AHPGDPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | NPC1 566/4885RAB9A 2981/4885HPGD 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.